Identifying sub-optimal responses to ivermectin in the treatment of River Blindness

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 39, 2009, Pages 16716-16721

  Churcher, Thomas S ^a   Pion, Sébastien D S ^b   Osei Atweneboana, Mike Y ^c,d   Prichard, Roger K ^c   Awadzi, Kwablah ^e   Boussinesq, Michel ^b   Collins, Richard C ^f   Whitworth, James A ^g   Basáñez, María Gloria ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c MCGILL UNIVERSITY   (Canada)

^d West African Science Service Centre on Climate Change and Adapted Land Use   (Ghana)

^e Hohoe Hospital   (Ghana)

^f Wellcome Trust ^*  (United States)

^g WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Drug resistance; Helminth parasites; Onchocerca volvulus; Overdispersion

Indexed keywords

IVERMECTIN;

ARTICLE; DRUG EFFICACY; HUMAN; MATHEMATICAL MODEL; MICROFILARIA; MOLECULAR GENETICS; ONCHOCERCIASIS; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANIMALS; FILARICIDES; HOST-PARASITE INTERACTIONS; HUMANS; IVERMECTIN; MODELS, THEORETICAL; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS, OCULAR; SKIN;

ONCHOCERCA VOLVULUS; VERMES;

EID: 70349734663     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906176106     Document Type: Article

References (43)

1. Kaplan RM (2004) Drug resistance in nematodes of veterinary importance: A status report. Trends Parasitol 20:477-481.
2. Albonico M, et al. (2003) Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull WHO 81:343-352. (Pubitemid 36644260)
3. Ali MMM, et al. (2002) Immunocompetence may be important in the effectiveness of Mectizan (R) (ivermectin) in the treatment of human onchocerciasis. Acta Trop 84:49-53.
4. Awadzi K, et al. (2004) Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 98:359-370. (Pubitemid 38903480)
5. Awadzi K, et al. (2004) An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 98:231-249. (Pubitemid 38594732)
6. De Clercq D, et al. (1997) Failure of mebendazole in treatment of human hookworm infections in the southern region of Mali. Am J Trop Med Hyg 57:25-30. (Pubitemid 27305178)
7. Eberhard ML, Lammie PJ, Dickinson CM, Roberts JM (1991) Evidence of nonsusceptibility to diethylcarbamazine in Wuchereria bancrofti. J Infect Dis 163:1157-1160.
8. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK (2007) Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: A two-phase epidemiological study. Lancet 369:2021-2029.
9. Churcher TS, Basáñez MG (2009) Sampling strategies to detect anthelmintic resistance: The perspective of human onchocerciasis. Trends Parasitol 25:11-17.
10. Martin PJ, Anderson N, Jarrett RG (1989) Detecting benzimidazole resistance with faecal egg count reduction tests and in vitro assays. Aust Vet J 66:236-240.
11. Dadzie Y, Neira M, Hopkins D (2003) Final report of the conference on the eradicability of Onchocerciasis. Filaria J 2:2. (Pubitemid 38751369)
12. Basáñez MG, et al. (2008) Effect of single-dose ivermectin on Onchocerca volvulus: A systematic review and meta-analysis. Lancet Infect Dis 8:310-322. (Pubitemid 351615758)
13. Plaisier AP, et al. (1995) Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis 172:204-210.
14. Bottomley C, Isham V, Collins RC, Basáñez MG (2008) Rates of microfilarial production by Onchocerca volvulus are not cumulatively reduced by multiple ivermectin treatments. Parasitology 135:1571-1581.
15. Cupp E, Richards F, Lammie P, Eberhard M (2007) Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 370:1123; author reply 1124-1125. (Pubitemid 47464571)
16. Mackenzie CD (2007) Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 370:1123; author reply 1124-1125.
17. Remme JH, Amazigo U, Engels D, Barryson A, Yaméogo L (2007) Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 370:1123-1124; author reply 1124-1125. (Pubitemid 47464573)
18. Cupp EW, et al. (1992) The effects of repetitive community-wide ivermectin treatment on transmission of Onchocerca volvulus in Guatemala. Am J Trop Med Hyg 47:170-180.
19. Collins RC, , et al. (1992) Ivermectin: Reduction in prevalence and infection intensity of Onchocerca volvulus following biannual treatments in five Guatemalan communities. Am J Trop Med Hyg 47:156-169.
20. Filipe JAN, et al. (2005) Human infection patterns and heterogeneous exposure in river blindness. Proc Natl Acad Sci USA 102:15265-15270.
21. Timmann C, et al. (2008) Human genetic resistance to Onchocerca volvulus: Evidence for linkage to chromosome 2p from an autosome-wide scan. J Infect Dis 198:427-433.
22. Hoerauf A, Brattig N (2002) Resistance and susceptibility in human onchocerciasis - beyond Th1 vs. Th2. Trends Parasitol 18:25-31. (Pubitemid 34155307)
23. Basáñez MG, Boussinesq M (1999) Population biology of human onchocerciasis. Philos Trans R Soc London B 354:809-826.
24. ToéL, et al. (1998) Detection of Onchocerca volvulus infection by O-150 polymerase chain reaction analysis of skin scratches. J Infect Dis 178:282-285. (Pubitemid 28328109)
25. Kershaw WE, Duke BOL, Budden FH (1954) Distribution of microfilariae of Onchocerca volvulus in the skin; its relation to the skin changes and to eye lesions and blindness. Br Med J 2:724-729.
26. Picq JJ, Jardel JP (1974) A method of evaluating microfilaria densities of Onchocerca volvulus Leuckart, 1893, in onchoceriasis patients. Bull WHO 51:145-153.
27. Fulford AJ (1994) Dispersion and bias: Can we trust geometric means? Parasitol Today 10:446-448.
28. Mathieu E, et al. (2003) Comparison of methods for estimating drug coverage for filariasis elimination, Leogane Commune, Haiti. Trans R Soc Trop Med Hyg 97:501-505. (Pubitemid 40590078)
29. Renz A, Fuglsang H, Anderson J (1987) Studies on the dynamics of transmission of onchocerciasis in a Sudan-savanna area of North Cameroon IV. The different exposure to Simulium bites and transmission of boys and girls and men and women, and the resulting manifestations of onchocerciasis. Ann Trop Med Parasitol 81:253-262. (Pubitemid 17120314)
30. Soboslay PT, et al. (1994) Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection. Clin Exp Immunol 96:238-244.
31. Duerr HP, Dietz K, Schulz-Key H, Büttner DW, Eichner M (2003) Density-dependent parasite establishment suggests infection-associated immunosuppression as an important mechanism for parasite density regulation in onchocerciasis. Trans R Soc Trop Med Hyg 97:242-250. (Pubitemid 37265641)
32. Bourguinat C, et al. (2007) Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis 1:e7. (Pubitemid 352024669)
33. Bourguinat C, et al. (2008) P-glycoprotein-like protein, a possible genetic marker for ivermectin resistance selection in Onchocerca volvulus. Mol Biochem Parasitol 158:101-111. (Pubitemid 351255520)
34. Taylor MJ, Hoerauf A (2001) A new approach to the treatment of filariasis. Curr Opin Infect Dis 14:727-731.
35. Danso-Appiah A, De Vlas SJ (2002) Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol 18:125-129. (Pubitemid 34164257)
36. Awadzi K, et al. (1986) The chemotherapy of onchocerciasis. XI. A double-blind comparative study of ivermectin, diethylcarbamazine and placebo in human onchocerciasis in northern Ghana. Ann Trop Med Parasitol 80:433-442. (Pubitemid 16077667)
37. Awadzi K, Dadzie KY, Kläger S, Gilles HM (1989) The chemotherapy of onchocerciasis. XIII. Studies with ivermectin in onchocerciasis patients in northern Ghana, a region with long lasting vector control. Trop Med Parasitol 40:361-366. (Pubitemid 19251013)
38. Awadzi K, Opoku NO, Addy ET, Quartey BT (1995) The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol 46:131-137.
39. Awadzi K, et al. (1997) The safety and efficacy of amocarzine in African onchocerciasis and the influence of ivermectin on the clinical and parasitological response to treatment. Ann Trop Med Parasitol 91:281-296. (Pubitemid 27214219)
40. Greene BM, et al. (1991) A comparison of 6-, 12-, and 24-monthly dosing with ivermectin for treatment of onchocerciasis. J Infect Dis 163:376-380.
41. Whitworth JA, Morgan D, Maude GH, Downham MD, Taylor DW (1991) A community trial of ivermectin for onchocerciasis in Sierra Leone: Clinical and parasitological responses to the initial dose. Trans R Soc Trop Med Hyg 85:92-96.
42. Boussinesq M, Chippaux JP (2001) A controlled prospective trial of the prophylactic effect of a single dose of ivermectin against Onchocerca volvulus. Parasite 8:255-259. (Pubitemid 33629565)
43. Duke BOL (1993) The population dynamics of Onchocerca volvulus in the human host. Trop Med Parasitol 44:61-68. (Pubitemid 23187702)